ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib.
Adult
Anaplastic Lymphoma Kinase
/ antagonists & inhibitors
Carbazoles
/ administration & dosage
Carcinoma, Non-Small-Cell Lung
/ diagnosis
Clinical Trials, Phase II as Topic
Disease Progression
Drug Administration Schedule
Drug Resistance, Neoplasm
Female
Humans
Lung Neoplasms
/ diagnosis
Male
Middle Aged
Organophosphorus Compounds
/ administration & dosage
Piperidines
/ administration & dosage
Progression-Free Survival
Protein Kinase Inhibitors
/ administration & dosage
Pyrimidines
/ administration & dosage
Quality of Life
Response Evaluation Criteria in Solid Tumors
Sulfones
/ administration & dosage
alectinib
anaplastic lymphoma kinase
brigatinib
ceritinib
neoplasm drug resistance
non-small-cell lung cancer
tyrosine kinase inhibitors
Journal
Future oncology (London, England)
ISSN: 1744-8301
Titre abrégé: Future Oncol
Pays: England
ID NLM: 101256629
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
pubmed:
12
2
2021
medline:
9
11
2021
entrez:
11
2
2021
Statut:
ppublish
Résumé
Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) have improved outcomes in Lay abstract Tyrosine kinase inhibitor medications (like crizotinib, alectinib or ceritinib) may work as the first treatment for people with non-small-cell lung cancer (NSCLC) that has spread to other parts of the body and has the ALK+ mutation (ALK+ NSCLC) in tumor testing. However, after a while, many people stop responding to treatment with one of these medicines. Brigatinib is a tyrosine kinase inhibitor medicine that may be effective in people with ALK+ NSCLC who have stopped responding to alectinib or ceritinib treatment. We describe the need for and design of a study of brigatinib in people with ALK+ NSCLC whose disease got worse on alectinib or ceritinib.
Autres résumés
Type: plain-language-summary
(eng)
Lay abstract Tyrosine kinase inhibitor medications (like crizotinib, alectinib or ceritinib) may work as the first treatment for people with non-small-cell lung cancer (NSCLC) that has spread to other parts of the body and has the ALK+ mutation (ALK+ NSCLC) in tumor testing. However, after a while, many people stop responding to treatment with one of these medicines. Brigatinib is a tyrosine kinase inhibitor medicine that may be effective in people with ALK+ NSCLC who have stopped responding to alectinib or ceritinib treatment. We describe the need for and design of a study of brigatinib in people with ALK+ NSCLC whose disease got worse on alectinib or ceritinib.
Identifiants
pubmed: 33569983
doi: 10.2217/fon-2020-1119
doi:
Substances chimiques
Carbazoles
0
Organophosphorus Compounds
0
Piperidines
0
Protein Kinase Inhibitors
0
Pyrimidines
0
Sulfones
0
ALK protein, human
EC 2.7.10.1
Anaplastic Lymphoma Kinase
EC 2.7.10.1
brigatinib
HYW8DB273J
ceritinib
K418KG2GET
alectinib
LIJ4CT1Z3Y
Banques de données
ClinicalTrials.gov
['NCT03535740']
Types de publication
Clinical Trial Protocol
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1709-1719Subventions
Organisme : ARIAD Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited